Hydrogen sulfide reduces oxidative stress in Huntington’s disease via Nrf2

Zige Jiang,Dexiang Liu,Tingting Li,Chengcheng Gai,Danqing Xin,Yijing Zhao,Yan Song,Yahong Cheng,Tong Li,Zhen Wang

DOI: https://doi.org/10.4103/nrr.nrr-d-23-01051

2024-01-31

Neural Regeneration Research

Abstract:Abstract The pathophysiology of Huntington’s disease involves high levels of the neurotoxin quinolinic acid (Quin). Quin accumulation results in oxidative stress, which leads to neurotoxicity. However, the molecular and cellular mechanisms by which Quin contributes to Huntington’s disease pathology remain unknown. In this study, we established in vitro and in vivo models of Huntington’s disease by administering Quin to the PC12 neuronal cell line and the striatum of mice, respectively. We observed a decrease in the levels of hydrogen sulfide (H 2 S) in both PC12 cells and mouse serum, which was accompanied by down-regulation of cystathionine β-synthase, an enzyme responsible for H 2 S production. However, treatment with NaHS (a H 2 S donor) increased H 2 S levels in the neurons and in mouse serum, as well as cystathionine β-synthase expression in the neurons and the mouse striatum, while also improving oxidative imbalance and mitochondrial dysfunction in PC12 cells and the mouse striatum. These beneficial effects correlated with upregulation of nuclear factor erythroid 2-related factor 2 (Nrf2) expression. Finally, treatment with the Nrf2 inhibitor ML385 reversed the beneficial impact of exogenous H 2 S on Quin-induced oxidative stress. Taken together, our findings show that H 2 S reduces oxidative stress in Huntington’s disease by activating Nrf2, suggesting that H 2 S is a novel neuroprotective drug candidate for treating patients with Huntington’s disease.

neurosciences,cell biology